Obesity

AGA updates MASLD care pathway

• by Doug Brunk

A two-tier strategy is recommended using noninvasive tests to identify patients who require specialty evaluation.

Tirzepatide outperforms semaglutide for weight loss

• by Julie Greenbaum

Real-world data show greater weight loss with dual incretin therapy.

Time-restricted feeding linked to improvements in Crohn’s disease

• by Sierra Rendon

Randomized study suggests meal timing strategy may complement standard therapy in select patients.

Pediatric MASLD tied to early morbidity

• by Doug Brunk

Review details rising prevalence and early fibrosis risk.

Study: Income, BMI linked to CCE completion

• by Doug Brunk

Danish screening data identify clinical and socioeconomic factors that significantly influence the likelihood of a complete colon capsule examination.

Global MASH costs set to double by 2040

• by Doug Brunk

A multinational modeling study projects sharp rises in advanced liver disease, deaths and health care spending tied to MASH across nine countries.

GLP-1 drugs pose no cancer risk, review finds

• by Doug Brunk

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

GI experts debate ESG, GLP-1 roles in modern obesity treatment strategies

• by Gyanprakash A. Ketwaroo, MD, MSc, Marianna T. Papademetriou, MD, Dan Maselli, MD, D-ABOM, Eric J. Vargas, MD, MS, D-ABOM

Dr. Marianna Papademetriou makes a strong case for embracing medical weight loss medications. Drs. Eric Vargas and Dan Maselli counter with an equally compelling defense of ESG, arguing that endobariatrics remains a vital, underused tool.

New credential elevates GI nutrition collaboration

• by Doug Brunk

To earn credential, dietitians must complete at least 2,000 hours of GI-focused practice and pass a specialty exam.

Approach to weight management in GI practice

• by Colleen R. Kelly, MD

As gastroenterologists, we treat a number of conditions that are caused or worsened by obesity.

Bariatric surgery vs GLP-1s: GERD risk

• by Kerri Miller

Propensity-matched analysis of over 80,000 patients reveals bariatric surgery nearly doubles five-year esophageal complication rates compared with GLP-1 RA therapy.

GLP-1s and tirzepatide: Similar GI risk

• by Kerri Miller

Real-world data show similar rates of severe GI events with semaglutide, dulaglutide, and tirzepatide, reinforcing comparable safety across agents in routine care.

'Don’t take shortcuts,' endoscopy researcher advises

• by Jennifer Lubell

Dr. Jovani compared two different types of needles for tissue acquisition with endoscopic ultrasound.

Mediterranean vs traditional diet for IBS

• by Kathryn Wighton

The Mediterranean diet demonstrated greater symptom relief and patient adherence than traditional dietary advice.

Nutritional IBD screening tools ranked

• by Kerri Miller

"MIRT might be the NSTs of choice to predict defined malnutrition and low-Fat Free Mass Index at 6 months follow-up in a cohort of inactive/mildly active IBD patients."

New data tie GLP-1 therapies to GERD

• by Jennifer Ford

"These potential risks should be weighed against the established clinical benefits of this drug class."

Remembering why we are in medicine

• by Judy A. Trieu, MD, MPH

Journal highlights: May-July 2025

• by Judy A. Trieu, MD, MPH

GLP-1 receptor agonist use in gastrointestinal endoscopy: A review of current evidence and guidelines

• by Sitharthan Sekar, MD, Nikiya Asamoah, MD

GI doc empowers female patients 'to be themselves'

• by Jennifer Lubell

Endoscopist brings cutting-edge tech to Asia-Pacific region

• by Jennifer Lubell

As the COVID-19 crisis unfolded, Tossapol Kerdsirichairat, MD, faced another challenge: his mother’s ovarian cancer diagnosis.

Alcohol hepatitis: Why females face higher risks

• by Kathryn Wighton

Study reveals rising hepatitis rates in young adults, with females facing greater risks of cirrhosis and liver-related death

Treating GERD: Lifestyle modifications vs medication

• by Gyanprakash A. Ketwaroo, MD, MSc, Juan D. Gomez, MD, Brijesh B. Patel, MD

While PPIs are highly effective, concerns about their potential side effects frequently make headlines.

An exciting time to be a gastroenterologist

• by Megan A. Adams, MD, JD, MSc 

The field of hepatology has shifted rapidly toward identifying and managing other significant causes of liver disease.

How to discuss lifestyle modifications in MASLD

• by Newsha Nikzad, MD, Daniel J. Huynh, BS, Nikki Duong, MD

Transitioning from employment in academia to private practice

• by Neil Gupta, MD

Medical, endoscopic, and surgical management of gastroesophageal reflux disease

• by Patrick Chang, MD, Supisara Tintara, MD, Jennifer Phan, MD

Obesity is not a moral failing, GI physician says

• by Jennifer Lubell

Which GI side effects should GLP-1 prescribers worry about?

• by David A. Johnson, MD

GLP-1 receptor agonists in endoscopy

• by GI and Hepatology News

Obesity in GI care

Investing in GI innovation

• by Megan A. Adams, MD, JD, MSc 

Weight loss management ... a new frontier?

• by Gyanprakash A. Ketwaroo, MD, MSc, GI and Hepatology News